Acurx Pharmaceuticals AI Stock Analysis
Want to see ACXP full AI Analyst Report?
Acurx Pharmaceuticals (ACXP) AI Stock Analysis
Acurx Pharmaceuticals
(NASDAQ:ACXP)
The score is held down primarily by weak financial performance (pre-revenue, persistent losses, and negative/volatile cash flow implying funding and dilution risk) and bearish technicals (below key moving averages with negative MACD). The earnings call provides a modest offset due to constructive regulatory and trial progress, but valuation support is limited given losses and no dividend.
Acurx Pharmaceuticals (ACXP) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $5.73M
- Dividend Yield
- ―
- Average Volume (3M)
- 123.47K
- Price to Earnings (P/E)
- -0.3
- Beta (1Y)
- -0.51
- Revenue Growth
- ―
- EPS Growth
- 71.66%
- Country
- US
- Employees
- 4
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Acurx Pharmaceuticals Business Overview & Revenue Model
Company Description
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a nove...
How the Company Makes Money
As a clinical-stage company, Acurx does not have a broadly established, recurring product-revenue base from marketed drugs; its business model is centered on advancing drug candidates through clinical development with the goal of eventual commerciali...
Acurx Pharmaceuticals Earnings Call Summary
The call was predominantly positive, centered on the start of the fully funded PATHFINDER trial, favorable preclinical and microbiome findings, FDA openness to further discussions regarding a potential NDA pathway, expanded intellectual property, and sufficient funding for the current recurrent CDI trial. The main challenges were higher R&D spending, continued net losses, dependence on future funding and clinical data to determine the Phase III pathway, unresolved partnership activity, NASDAQ listing compliance efforts, and the expected timing of a recurrent CDI trial update in the second half of 2027.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management said the FDA is open to further discussion at a pre NDA meeting after completion of the single Phase III ASPIRE trial and data from the 20-patient Pathfinder trial, and that a successful Pathfinder trial may support a smaller Phase III program or Pathfinder 2 under the FDA’s LPAD pathway. Acurx said it has enough funds to pay for the rCDI trial, assuming the trial is fully enrolled in the third quarter of 2027, has 12 months of funds secured, and may raise cash in the next 12 months through ELOC drawdowns, equity offerings, partnerships or government grants; an update is expected when enrollment is completed sometime in the second half of 2027. If the ASPIRE trial receives a government grant, the company said it would start that trial right away; if it is not funded and rCDI data is good, FDA may give the green light to continue with Pathfinder 2. Depending on data from the 20 patient trial, Pathfinder 2 may be in the neighborhood of 350 patients in total, may take 1.5 or 2 years to fully enroll, would be an international study, and would use an active comparator currently considering VOWST as a lead possibility.
Acurx Pharmaceuticals Financial Statement Overview
Summary
Financial durability is weak due to a pre-revenue model, ongoing net losses, and consistently negative operating/free cash flow. The debt-free balance sheet and improved equity provide some cushion, but the unusually large and volatile recent cash outflows materially increase financing/dilution risk.
Income Statement
12Very NegativeBalance Sheet
46NeutralCash Flow
8Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -7.56M | -7.97M | 20.12K | -14.58M | -12.09M | -12.75M |
| Net Income | -7.51M | -7.97M | -14.10M | -14.58M | -12.09M | -12.75M |
Balance Sheet | ||||||
| Total Assets | 10.98M | 7.69M | 3.86M | 7.71M | 9.38M | 13.25M |
| Cash, Cash Equivalents and Short-Term Investments | 10.66M | 7.56M | 3.71M | 7.47M | 9.11M | 12.96M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.83M | 2.42M | 3.24M | 3.04M | 2.06M | 843.91K |
| Stockholders Equity | 8.15M | 5.27M | 615.12K | 4.67M | 7.32M | 12.41M |
Cash Flow | ||||||
| Free Cash Flow | -6.18M | -6.79M | -10.38M | -9.80M | -7.54M | -5.01M |
| Operating Cash Flow | -6.18M | -6.79M | -10.38M | -9.80M | -7.54M | -5.01M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 10.78M | 10.64M | 6.62M | 8.16M | 3.70M | 14.80M |
Acurx Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACXP, the sentiment is Negative. The current price of 1.03 is below the 20-day moving average (MA) of 1.08, below the 50-day MA of 1.23, and below the 200-day MA of 1.91, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 39.14 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACXP.
Acurx Pharmaceuticals Risk Analysis
Acurx Pharmaceuticals disclosed 54 risk factors in its most recent earnings report. Acurx Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAcurx Pharmaceuticals Peers Comparison
Overall Rating
COCP45Neutral
CTXR43Neutral
SNGX43Neutral- ACXP43Neutral
ALGS40Underperform
GOVX39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| COCP | 45Neutral | $19.84M | -1.27 | -207.47% | ― | ― | 38.55% |
| CTXR | 43Neutral | $13.53M | -0.23 | -67.15% | ― | ― | 57.48% |
| SNGX | 43Neutral | $7.48M | -0.43 | -165.88% | ― | ― | 79.77% |
| ACXP | 43Neutral | $5.78M | -0.29 | -124.74% | ― | ― | 71.66% |
| ALGS | 40Underperform | $18.11M | -0.34 | -206.30% | ― | 1171.58% | 49.20% |
| GOVX | 39Underperform | $32.67M | -0.01 | -743.66% | ― | -100.00% | 77.63% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ACXP | Acurx Pharmaceuticals Llc | 1.03 | -3.56 | -77.56% | |
| SNGX | Soligenix Inc | 0.32 | -1.05 | -76.57% | |
| GOVX | Geovax Labs, Inc. | 2.16 | -268.50 | -99.20% | |
| COCP | Cocrystal Pharma | 1.02 | -0.01 | -0.97% | |
| CTXR | Citius Pharma | 0.48 | -0.50 | -50.97% | |
| ALGS | Aligos Therapeutics, Inc. | 2.16 | -4.50 | -67.57% |
Acurx Pharmaceuticals Corporate Events
Acurx Pharmaceuticals Lowers Quorum for Shareholder Meetings
PositiveOn October 29, 2026, Acurx Pharmaceuticals, Inc.’s Board of Directors approved and adopted an amendment to the company’s bylaws that lowered the stockholder meeting quorum requirement. The threshold was reduced from a majority of shares entitled to v...
Acurx Pharmaceuticals Shareholders Approve Governance and Auditing Changes
PositiveAt the October 16, 2026 Annual Meeting of Stockholders of Acurx Pharmaceuticals, Inc., a quorum was achieved with approximately 52.83% of the 5,471,297 outstanding common shares represented in person or by proxy. Stockholders considered two corporate...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 12, 2026